Time to deterioration
PD‐L1, tumor, Cancer
LUNG CANCER, EVENT, TUMOR, CANCER
The tislelizumab arm had a significantly lower risk of experiencing a deterioration event relative to the docetaxel arm for the QLQ‐C30 GHS/QoL score hazard ratio (HR: 0.77 [95% CI: 0.574–1.026], Time to Deterioration for GHS/QoL and the EORTC QLQ‐LC13.Abbreviations: CI, confidence interval; EORTC QLQ‐LC13, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 items; GHS/QOL, global health status/quality of life; HR, hazard ratio; NE, not estimated; NR, not reached.Stratification factors: histology (squamous versus non‐squamous), lines of therapy (second versus third), and PD‐L1 expression (≥25% versus <25% tumor cells).